



ASX Announcement 24 April, 2007

DIA-B ANNOUNCES U.S. GRANTED PATENT FOR ISF402

Dia-B Tech Limited (ASX: DIA) today announced that the United States Patent and Trademark Office has granted a patent that protects ISF402 and the use thereof in the treatment of type 2 diabetes.

The U.S. 7,173,012 patent, entitled “Hypoglycaemic peptides and methods of use thereof” provides Dia-B with a proprietary position in the United States until 2022.

Ken Smith, Dia-B Tech CEO said, “This is another very positive step for Dia-B in our ISF402 program, and further enhances our patent position. Together with the recently-announced progress in the phase 1 human trials of ISF402, Dia-B is entering a significant stage of our development. 2007 shapes up as an exciting year for Dia-B and our research into the global diabetes epidemic.”

The patent applications for ISF402 are still pending before the relevant patent offices in Australia and Europe. The patent has also been granted in New Zealand as New Zealand patent number 530192.

For more information, please contact:

Ken Smith, CEO

Dia-B Tech Limited

ACN 102 456 048

Tel: +61 3 8862 6319

Fax: +61 3 8862 6610

Mob: 0412 190 908

www.dia-btech.com.au